Myasthenia gravis: The evolving therapeutic landscape
Pharmacological options in the management of generalized myasthenia gravis (gMG) have expanded rapidly in the last 7 years. There are now several complement inhibitors and neonatal Fc receptor antagonists on the market in many countries for patient management, following the successful completion of...
Saved in:
| Main Authors: | Gil I. Wolfe, Jonathan E. Hanson, Nicholas J. Silvestri |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | eNeurologicalSci |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405650224000480 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Single‐cell atlas reveals heterogeneous response to FcRn blockade in anti‐AChR antibody‐positive generalised myasthenia gravis
by: Hui‐Ning Li, et al.
Published: (2025-08-01) -
The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis
by: Jia-Jun Cheng, et al.
Published: (2025-08-01) -
Myasthenia gravis in children: analysis of 18 patients
by: Morita Maria da Penha A., et al.
Published: (2001-01-01) -
Surgical effect and prognostic factors of myasthenia gravis with thymomas
by: Wenxin Tian, et al.
Published: (2020-05-01) -
Epidemiologic studies of myasthenia gravis: literature review
by: T. M. Alekseeva, et al.
Published: (2018-10-01)